The impact of antimicrobial resistance: Changing epidemiology of community-acquired respiratory-tract infections

American Journal of Health-System Pharmacy

Volumn 56, Issue 22 SUPPL. 3, 1999, Pages

  Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Anti infective agents; Haemophilus influenzae; Moraxella catarrhalis; Quinolones; Resistance; Respiratory tract infections; Streptococcus pneumoniae

Indexed keywords

AMPICILLIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; EVERNIMICIN; GATIFLOXACIN; GLYCOPEPTIDE; LEVOFLOXACIN; LINEZOLID; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; STREPTOGRAMIN; TETRACYCLINE; TIGECYCLINE; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0033571414     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/56.suppl_3.s4     Document Type: Conference Paper

References (59)

1. Weinstein RA. Nosocomial infection update. Emerg Infect Dis. 1998; 4:416-20.
2. Bartlett J, Mundy L. Community-acquired pneumonia. N Engl J Med. 1995; 333:1618-24.
3. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA. 1995; 273:214-9.
4. Neu HC. The crisis in antibiotic resistance. Science. 1992; 257:1064-73.
5. Schwartz B, Bell DM, Hughes JM. Preventing the emergence of antimicrobial resistance: a call for action by clinicians, public health officials, and patients. JAMA. 1997; 278:944-5.
6. Bartlett JG, Breiman RF, Mandell LA et al. Community-acquired pneumonia in adults:guidelines for management. Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 1998; 26:811-38.
7. Brown PD, Lerner SA. Community-acquired pneumonia. Lancet. 1998; 352:1295-302.
8. Fine MJ, Chowdhry T, Ketema A. Outpatient management of community-acquired pneumonia. Hosp Pract (Off Ed). 1998; 33:123-33.
9. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med. 1995; 99:3S-7S.
10. Acar JF. Resistance patterns of Haemophilus influenzae. J Chemother. 1999; 11(suppl 1):44-50.
11. Bell DM, Drotman DP. Confronting antimicrobial resistance: a shared goal of family physicians and the CDC. Am Fam Physician. 1999; 59:2097-8.
12. Jacoby GA. Prevalence and resistance mechanisms of common bacterial respiratory pathogens. Clin Infect Dis. 1994; 18:951-7.
13. Mevius DJ, Sprenger MJ, Wegener HC. EU conference, "the microbial threat." Int J Antimicrob Agents. 1999; 11:101-5.
14. Turnidge JD, Bell JM, Collignon PJ. Rapidly emerging antimicrobial resistances in Streptococcus pneumoniae in Australia. Pneumococcal Study Group. Med J Aust. 1999; 170:152-5.
15. Thornsberry C. Emerging resistance in clinically important gram-positive cocci. West J Med. 1996; 164:28-32.
16. Pfaller MA, Jones RN, Doern GV et al. Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. Diagn Microbiol Infect Dis. 1999; 33:283-97.
17. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992; 15:77-83.
18. Spika JS, Facklam RR, Plikaytis BD et al. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group. J Infect Dis. 1991; 163:1273-8.
19. Mufson MA. Penicillin-resistant Streptococcus pneumoniae increasingly threatens the patient and challenges the physician. Clin Infect Dis. 1998; 27:771-3.
20. Breiman RF, Butler JC, Tenover FC et al. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994; 271:1831-5.
21. Butler JC, Hofmann J, Cetron MS et al. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis. 1996; 174:986-93.
22. Doern GV, Brueggemann A, Holley HP Jr et al. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996; 40:1208-13.
23. Jones RN, Ballow CH, Biedenbach DJ et al. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis. 1998; 31:437-51.
24. SENTRY TSASP. The SENTRY database, 1997 and 1998. 1999.
25. Thornsberry C, Ogilvie P, Kahn J et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. Diagn Microbiol Infect Dis. 1997; 29:249-57.
26. Doern GV, Pfaller MA, Kugler K et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis. 1998; 27:764-70.
27. Campbell GD Jr, Silberman R. Drug-resistant Streptococcus pneumoniae. Clin Infect Dis. 1998; 26:1188-95.
28. Felmingham D, Washington J. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens - findings of the Alexander Project 1992-1996. J Chemother. 1999; 11(suppl 1):5-21.
29. Jones RN, Low DE, Pfaller MA. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn Microbiol Infect Dis. 1999; 33:101-12.
30. Spach DH, Black D. Antibiotic resistance in community-acquired respiratory tract infections: current issues. Ann Allergy Asthma Immunol. 1998; 81:293-302.
31. Cunha BA, Shea KW. Emergence of antimicrobial resistance in community-acquired pulmonary pathogens. Semin Respir Infect. 1998; 13:43-53.
32. Klugman K, Goldstein F, Kohno S et al. The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci. Clin Microbiol Infect. 1997; 3(suppl 1):S48-60.
33. McDougal LK, Rasheed JK, Biddle JW et al. Identification of multiple clones of extended-spectrum cephalosporin-resistant Streptococcus pneumoniae isolates in the United States. Antimicrob Agents Chemother. 1995; 39:2282-8.
34. Courvalin P, Carlier C. Transposable multiple antibiotic resistance in Streptococcus pneumoniae. Mol Gen Genet. 1986; 205:291-7.
35. Burdett V. Streptococcal tetracycline resistance mediated at the level of protein synthesis. J Bacteriol. 1986; 165:564-9.
36. Burdett V. Purification and characterization of Tet(M), a protein that renders ribosomes resistant to tetracycline. J Biol Chem. 1991; 266:2872-7.
37. Hooper DC. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. Clin Infect Dis. 1998; 27(suppl 1):S54-63.
38. Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1999; 43:410-2.
39. Doern GV, Pfaller MA, Erwin ME et al. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada - 1997 results from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis. 1998; 32:313-6.
40. Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 1995; 8:557-84.
41. Doern GV, Jones RN, Pfaller MA et al. Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). Antimicrob Agents Chemother. 1999; 43:385-9.
42. Doern GV, Jorgensen JH, Thornsberry C et al. National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae. Antimicrob Agents Chemother. 1988; 32:180-5.
43. File TM Jr, Tan JS. Community-acquired pneumonia. The changing picture. Postgrad Med. 1992; 92:197-8,201-8,11-4.
44. Schrock J, Hackman BA, Plouffe JF. Susceptibility of ninety-eight clinical isolates of Legionella to macrolides and quinolones using the Etest. Diagn Microbiol Infect Dis. 1997; 28:221-3.
45. Dubois J, St-Pierre C. In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species. Diagn Microbiol Infect Dis. 1999; 33:261-5.
46. Gaynes R, Monnet D. The contribution of antibiotic use on the frequency of antibiotic resistance in hospitals. Ciba Found Symp. 1997; 207:47-56.
47. Emori TG, Culver DH, Horan TC et al. National Nosocomial Infections Surveillance System (NNIS): description of surveillance methods. Am J Infect Control. 1991; 19:19-35.
48. Pfaller MA, Jones RN, Doern GV et al., the SENTRY Participants Group. Bacterial pathogens isolated from patients with blood-stream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 1998; 42:1762-70.
49. Jacobs MR, Koornhof HJ, Robins-Browne RM et al. Emergence of multiply resistant pneumococci. N Engl J Med. 1978; 299:735-40.
50. Performance standards for antimicrobial susceptibility testing. Eighth information supplement, M100-S8. Wayne, PA: National Committee for Clinical Laboratory Standards; 1997.
51. Baquero F. Pneumococcal resistance to beta-lactam antibiotics: a global geographic overview. Microb Drug Resist. 1995; 1:115-20.
52. Jones RN, Pfaller MA, Doern GV et al., the SENTRY Participants Group. Antimicrobial activity of gatifloxacin, a newer 8-methoxy fluoroquinolone, tested against over 23,000 recent clinical isolates from the SENTRY Antimicrobial Surveillance Program, 1997. Paper presented at 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA; 1998 Sep 24-27.
53. Topkis S, Swarz H, Breisch SA et al. Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia. Clin Ther. 1997; 19:975-88.
54. Carbon C, Leophonte P, Petitpretz P et al. Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1992; 36:833-9.
55. Martin SJ, Meyer JM, Chuck SK et al. Levofloxacin and sparfloxacin: new quinolone antibiotics. Ann Pharmacother. 1998; 32:320-36.
56. Marshall WF, Blair JE. The cephalosporins. Mayo Clin Proc. 1999; 74:187-95.
57. Schlick W. The problems of treating atypical pneumonia. J Antimicrob Chemother. 1993; 31(suppl C):111-20.
58. Jones RN, Marshall SA, Pfaller MA et al. Activity and spectrum of ziracin (SCH27899) tested against nonfastidious gram-positive species including recommendations for routine susceptibility test methods. Paper presented at 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA; 1998 Sep 24-27.
59. Swaney SM, Shinabarger DL, Schaadt RD et al. Oxazolidinone resistance is associated with a mutation in the peptidyl transferase region of 23S rRNA. Paper presented at 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA; 1998 Sep 24-27.